In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Comparison of laboratory efficacy of P2Y12 receptor antagonists and predictors of high on-treatment platelet reactivity.

Session Poster session 7

Speaker Zuzana Motovska

Event : ESC Congress 2014

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes – Pathophysiology and Mechanisms
  • Session type : Poster Session

Authors : Z Motovska (Prague,CZ), M Ondrakova (Prague,CZ), J Ulman (Prague,CZ), M Maly (Prague,CZ), J Knot (Prague,CZ), F Bednar (Prague,CZ), P Widimsky (Prague,CZ)

Authors:
Z. Motovska1 , M. Ondrakova1 , J. Ulman1 , M. Maly2 , J. Knot1 , F. Bednar1 , P. Widimsky1 , 1Charles University Prague, 3rd Faculty of Medicine, Faculty Hospital Kralovske Vinohrady - Prague - Czech Republic , 2National Institute of Public Health - Prague - Czech Republic ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 1166

Objective: To compare the laboratory efficacy of P2Y12 receptor antagonists and to identify predictors of high on-treatment platelet reactivity (HTPR) in patients with an acute coronary syndrome treated with stent-PCI.

Methods: An analysis of PCI-VASP “all-comer” registry was performed. Efficacy of P2Y12 receptor antagonists was measured by phosphorylation of VASP 24±4 hours after a loading dose (LD) of clopidogrel (600mg), prasugrel (60mg) and ticagrelor (180mg), and expressed through a platelet reactivity index (PRI). High on-treatment platelet reactivity (HTPR) was defined as PRI ≥50%.

Results: Study group consisted of 589 patients who received clopidogrel (N=407, age 67±12.9 ys, 63.6% males), prasugrel (N=106, age 61.8±11.7 ys, 71.4% males) or ticagrelor (N=76, age 65.8±13.3 ys, 67.1% males). Patients selected for therapy with prasugrel were significantly younger than those who received clopidogrel (p=0.001).

Mean PRI was 44.2±23.1% after clopidogrel, 17.7±18.0% after prasugrel, and 18.8±17.0% after ticagrelor; p<0.001 for comparison of clopidogrel vs. prasugrel, and clopidogrel vs. ticagrelor, resp.). Proportion of patients with HTPR was 42.2% in clopidogrel group, 9.4% in prasugrel group, and 7.9% in ticagrelor group; p<0.001 for comparison of clopidogrel vs. prasugrel, and clopidogrel vs. ticagrelor, resp.).

From multiple variables* tested in prediction of HTPR, we found that HTPR was in ticagrelor treated patients significantly related to the platelet count (p=0.014), mean platelet volume (p=0.029) and multivessel disease (p=0.023). HTPR in patients treated with prasugrel was significatly related only to the mean platelet volume (p=0.02).

*variables included in the model: age, gender, BMI; history of: hypertension, diabetes, hyperlipidemia, MI, CABG, PAD, stroke, family history of CAD, cigarette smoking, CKD; therapy with: statin, ACEI, betablocker; single vs. multivessel disease, number of implanted stents; serum urea, creatinin, estimated GFR, hemoglobin, platelet count, mean platelet volume.

Conclusion: Residual platelet reactivity and proportion of patients with HTPR after LD of prasugrel/ticagrelor were significantly lower than after LD of clopidogrel. Factors known as predictors of higher platet reactivity did not influence efficacy of new generation of P2Y12 receptor antagonists. Family history of coronary artery disease platelet count and mean platelet volume were the single variables significantly related to HTPR in patients treated with prasugrel/ticagrelor.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are